Mazor Robotics Ltd – (NASDAQ:MZOR) shares reached a new 52-week high on Thursday . The company traded as high as $21.47 and last traded at $21.24, with a volume of 171,193 shares trading hands. The stock had previously closed at $19.52.

A number of research analysts recently commented on the company. Standpoint Research assumed coverage on Mazor Robotics Ltd – in a report on Friday, July 8th. They issued a “buy” rating and a $30.00 price target on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics Ltd – in a research report on Wednesday, April 6th. Zacks Investment Research raised Mazor Robotics Ltd – from a “sell” rating to a “hold” rating and set a $22.00 target price on the stock in a research report on Tuesday, July 19th. Sterne Agee CRT lowered Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 31st. Finally, Wells Fargo & Co. raised Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $25.00.

The stock’s market cap is $480.55 million. The firm’s 50-day moving average price is $18.79 and its 200 day moving average price is $13.36.

Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.06. During the same period in the previous year, the firm posted ($0.11) earnings per share. The firm earned $6.40 million during the quarter, compared to analyst estimates of $6.63 million. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. On average, equities research analysts anticipate that Mazor Robotics Ltd – will post ($0.44) EPS for the current fiscal year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.